Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels.
Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KK. Dhiman A, et al. Among authors: karrison t. Ann Surg Oncol. 2022 Jan 5;29(7):4583-92. doi: 10.1245/s10434-021-11249-7. Online ahead of print. Ann Surg Oncol. 2022. PMID: 34988836 Free PMC article.
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE. Kindler HL, et al. Among authors: karrison t. Invest New Drugs. 2004 Aug;22(3):323-7. doi: 10.1023/B:DRUG.0000026259.28395.c2. Invest New Drugs. 2004. PMID: 15122080 Clinical Trial.
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R. Catenacci DV, et al. Among authors: karrison t. Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1. Cancer Biol Ther. 2011. PMID: 21543897 Free PMC article.
324 results